Aeterna Zentaris (AEZS) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Wall St futures gain as yields, oil prices ease ahead of jobs report
- Fed’s Jefferson sees no urgency for another rate increase
- Oil jumps 4% on reports China halts fuel exports, US troops head to Middle East
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Anthropic targets mid-November for public debut - report
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
Aeterna Zentaris Reports First Quarter 2017 Financial and Operating Results
May 8, 2017 4:30 PM EDTAll amounts are in US Dollars
Highlights
Company reported on May 1 that ZoptEC Phase 3 clinical study of ZoptrexTM (zoptarelin doxorubicin) did not achieve its primary endpoint; further development of product to be discontinued
Company announced on March 30 that, following its meeting with the FDA it intends to file a new drug application seeking approval of MacrilenTM (macimorelin) for the evaluation of growth hormone deficiency in adults
Adequate liquidity and resources to fund operations through expected Macrilen approval
$17.8 million of unrestricted... More